Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 15/20 | 0.51 |
| ▸ | SLC22A12 | Q96S37 | 3/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6301205 | 0.95 | PPARG (0.55) | PPARGSLC22A12PTPN1 | |
| SCHEMBL6300416 | 0.92 | SLC22A12 (0.51) | PPARGSLC22A12BCL2L1MCL1 | |
| SCHEMBL6300645 | 0.88 | SLC22A12 (0.49) | SLC22A12BCL2L1MCL1 | |
| SCHEMBL6306158 | 0.85 | PPARG (0.68) | PPARGSLC22A12 | |
| SCHEMBL6306639 | 0.84 | SLC22A12 (0.45) | PPARGSLC22A12BCL2L1MCL1 | |
| SCHEMBL6299437 | 0.84 | PPARG (0.57) | PPARGSLC22A12 | |
| SCHEMBL6299998 | 0.83 | SLC22A12 (0.52) | PPARGSLC22A12 | |
| SCHEMBL6134834 | 0.83 | SLC22A12 (0.47) | PPARGSLC22A12 | |
| SCHEMBL6134837 | 0.83 | SLC22A12 (0.47) | PPARGSLC22A12 | |
| SCHEMBL6298795 | 0.83 | PPARG (0.64) | PPARGSLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040180947-A1 | hypoglycemic activity or phoshodiesterase-V inhibitory activity; prophylaxis and treatment of impaired glucose tolerance disorder, diabetes (e.g., type II diabetes), diabetic complications | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180947-A1 | hypoglycemic activity or phoshodiesterase-V inhibitory activity; prophylaxis and treatment of impaired glucose tolerance disorder, diabetes (e.g., type II diabetes), diabetic complications | PDE2A, PDE3A, PYGM | PPARG 1366/4885SLC22A12 1685/4885PTPN1 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.